Business
Aldeyra Therapeutics Announces Improvement from Baseline in Retinal Function in Phase 2 Clinical Trial of ADX‑2191 in Patients with Retinitis Pigmentosa
Best Corrected and Low‑Light Visual Acuity Statistically Significantly Improved As Assessed by Electroretinography, Time to Retinal Response Statistically
About this update from Aldeyra Therapeutics, Inc.
[{"type":"text","content":"\n\nBest Corrected and Low‑Light Visual Acuity Statistically Significantly Improved\n\n\n\nAs Assessed by Electroretinography, Time to Retinal Response Statistically Significantly Improved\n\n\n\nAs Assessed by Macular and Dark-Adapted Perimetry, Retinal Sensitivity Statistically Significantly Improved\n\n\n\nADX‑2191 Was Well Tolerated and No Safety Concerns Were Identified\n\n\n\nPlanned Phase 2/3 Clinical Trial to be Discussed with Regulatory Authorities\n\n\n\nCompany to Discuss Results in Conference Call and Webcast at 8:00 a.m. ET Today\n\n\n\n LEXINGTON, Mass.--(BUSINESS WIRE)--\nAldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced positive top-line results from the Phase 2 clinical trial of intravitreal ADX-2191 (methotrexate injection, USP), an investigational drug candidate, in patients with retinitis pigmentosa. Relative to baseline, the clinical trial demonstrated statistically significant improvement in retinal function across a number of different physiological and psychophysical assessments.\n\n\n“The improvement in retinal function relative to baseline observed in this retinitis pigmentosa clinical trial of ADX-2191 may offer hope to patients that today have no therapeutic options,” stated Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra. “Based on compelling proof-of-concept clinical activity that is consistent with a well-defined mechanism of action supported by preclinical evidence, we are excited to meet with regulatory authorities to discuss initiation of a potentially pivotal Phase 2/3 clinical trial, as we enthusiastically advance ADX-2191 to the next stage of development.”\n\n\n\n\nBased on preclinical evidence suggesting that methotrexate may facilitate the clearance of mutated rhodopsin1, a protein critical for visual cycle function, an open-label, single-center Phase 2 clinical trial of ADX‑2191 was performed in eight retinitis pigmentosa patients with rhodopsin misfolding mutations. Over three months of treatment with ADX-2191, four patients received monthly injections and four patients received twice-monthly injections. The primary endpoint of the clinical trial was safety. Secondary endpoints included change from baseline in visual acuity; retinal fun...